Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bone Marrow Cancer Drug of Australia’s Cytopia Shows Promise

This article was originally published in PharmAsia News

Executive Summary

Australian biotech Cytopia Research's CYT387 drug for fighting a cancer-cell mutation associated with myeloproliferative disorders of the bone marrow has demonstrated efficacy in mouse studies. Researchers heading the Cytopia-funded study found the drug blocks the enzyme that causes the disorders and could become the first U.S.-approved drug targeting the major MPD bone-marrow cancers. The head researcher said there is a good chance of entering clinical trials next year with the drug, an inhibitor of the JAK-2-V617F enzyme. The three major MPDs are polyeythemia vera, essential thrombocythemia and primary myelofibrosis. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067379

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel